What does ImmuneSpec do?

ImmuneSpec is a research organisation in Niel. Private Limited, started on 27 January 2023, 1 establishment.

What is the address of ImmuneSpec?

The registered office of ImmuneSpec is located at Galileilaan 18 box 6, 2845 Niel.

Is ImmuneSpec still active?

Yes. According to the CBE (29 October 2026) ImmuneSpec is active, legal situation “Normale toestand”, started on 27 January 2023.

Is ImmuneSpec registered on Peppol?

Yes, ImmuneSpec is registered on the Peppol network with ID 0208:0797707610.

What is the enterprise number of ImmuneSpec?

The enterprise number of ImmuneSpec is BE0797707610.

When was ImmuneSpec founded?

ImmuneSpec was founded on 27 January 2023.

Who are the directors of ImmuneSpec?

According to the 2025 annual accounts, the directors of ImmuneSpec are: Elise Pepermans, Heran Partners BV, Thibault Jonckheere, Clean Vision Invest BV.

Is ImmuneSpec a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 January 2023; 3 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did ImmuneSpec make in 2025?

ImmuneSpec recorded a loss after taxes of € 201,723 in financial year 2025.

What is the revenue of ImmuneSpec?

As a small company, ImmuneSpec is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 883,559.

How much does an employee at ImmuneSpec earn?

The average wage cost per full-time employee at ImmuneSpec was € 65,900 in 2025: staff costs of € 375,519 for 5.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ImmuneSpec have?

According to the 2025 annual accounts, ImmuneSpec has 5.7 full-time equivalents (FTE).

ImmuneSpec (Private Limited) - Niel - BE0797707610

Dossier ImmuneSpec, printed on 29 October 2026 from databakkes.be/en/0797707610/immunespec. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Busy address KBO

11 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

ImmuneSpec from Niel, company number BE0797707610, closed financial year 2025 with a result of € -201,723 after tax. For that financial year ImmuneSpec recorded a gross margin of € 883,559 and equity of € 2.6 million. Compared with financial year 2024, the result moved from € -77,917 to € -201,723. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.

What it is worth Growing

€ 2.6 million

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -201,723

▼ 159 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 191,854

▲ 69% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -676,707.

People and assets in 2025

Full-time equivalents

5.7

▲ 2.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 375,519

▲ 82% vs 2024

€ 65,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 872,088

▼ 1% vs 2024

Of which on lease € 838,826.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 621,148

€ 235,929 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 143,084

▲ 34% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 64,774

▲ 94% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 51,531 Gross margin 2023: € 51,531 First fiscal year in the series	€ 696,858 Gross margin 2024: € 696,858 ▲ € 645,327 vs 2023 (€ 51,531) Favourable step	€ 883,559 Gross margin 2025: € 883,559 ▲ 27% vs 2024 (€ 696,858) Favourable step	▲ 27%
Profit after taxes	€ -397,068 Profit after taxes 2023: € -397,068 First fiscal year in the series	€ -77,917 Profit after taxes 2024: € -77,917 ▲ € 319,151 vs 2023 (€ -397,068) Favourable step	€ -201,723 Profit after taxes 2025: € -201,723 ▼ € 123,806 vs 2024 (€ -77,917) Unfavourable step	▼ € 123,806
Equity	€ 1,917,922 Equity 2023: € 1,917,922 First fiscal year in the series	€ 2,340,065 Equity 2024: € 2,340,065 ▲ 22% vs 2023 (€ 1,917,922) Favourable step	€ 2,638,403 Equity 2025: € 2,638,403 ▲ 13% vs 2024 (€ 2,340,065) Favourable step	▲ 13%
Total debts	€ 1,291,051 Total debts 2023: € 1,291,051 First fiscal year in the series	€ 838,684 Total debts 2024: € 838,684 ▼ 35% vs 2023 (€ 1,291,051) Favourable step	€ 896,755 Total debts 2025: € 896,755 ▲ 7% vs 2024 (€ 838,684) Unfavourable step	▲ 7%
Cash	€ 238,664 Cash 2023: € 238,664 First fiscal year in the series	€ 113,328 Cash 2024: € 113,328 ▼ 53% vs 2023 (€ 238,664) Unfavourable step	€ 191,854 Cash 2025: € 191,854 ▲ 69% vs 2024 (€ 113,328) Favourable step	▲ 69%
Retained profit	€ -397,068 Retained profit 2023: € -397,068 First fiscal year in the series	€ -474,985 Retained profit 2024: € -474,985 ▼ € 77,917 vs 2023 (€ -397,068) Unfavourable step	€ -676,707 Retained profit 2025: € -676,707 ▼ € 201,723 vs 2024 (€ -474,985) Unfavourable step	▼ € 201,723
Bank debt	€ 800,938 Bank debt 2023: € 800,938 First fiscal year in the series	€ 619,075 Bank debt 2024: € 619,075 ▼ 23% vs 2023 (€ 800,938) Favourable step	€ 621,148 Bank debt 2025: € 621,148 Unchanged (€ 619,075) Unfavourable step
Balance sheet total	€ 3,208,974 Balance sheet total 2023: € 3,208,974 First fiscal year in the series	€ 3,178,749 Balance sheet total 2024: € 3,178,749 ▼ 1% vs 2023 (€ 3,208,974) Unchanged	€ 3,535,158 Balance sheet total 2025: € 3,535,158 ▲ 11% vs 2024 (€ 3,178,749) Unchanged	▲ 11%
Employees (FTE)	1.7 Employees (FTE) 2023: 1.7 First fiscal year in the series	3.4 Employees (FTE) 2024: 3.4 ▲ 1.7 vs 2023 (1.7) Unchanged	5.7 Employees (FTE) 2025: 5.7 ▲ 2.3 vs 2024 (3.4) Unchanged	▲ 2.3

Key figures of ImmuneSpec, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ImmuneSpec?

What happened at ImmuneSpec in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 8, 2026 New annual accounts for financial year 2025: loss of € 201,723. Source: NBB ↗
2023 Clean Vision Invest BV became a director. NBB
2023 Thibault Jonckheere became a director. NBB
2023 Heran Partners BV became a director. NBB
Jan 27, 2023 New establishment in Niel. KBO
Jan 27, 2023 Start of the company according to the CBE. KBO
2023 Elise Pepermans became a director. NBB

In short

From € 397,068 loss in 2023 to € 201,723 loss in 2025.

On average € 155,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Heran HealthTech Fund I 38.4%

Clean Vision Invest 26.2%

The stake of Heran HealthTech Fund I, Clean Vision Invest comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

ImmuneSpec

Behind ImmuneSpec are Elise Pepermans, Heran Partners BV, Thibault Jonckheere and Clean Vision Invest BV. The shares are held by Heran HealthTech Fund I (38.4%) and Clean Vision Invest (26.2%).

Directors

According to the 2025 annual accounts

Elise Pepermans

Director

since 2023

Heran Partners BV

Director · represented by Geoffrey D'hondt

Also active at: Lynxcare Clinical Informatics, FOx Biosystems, ASPECT ANALYTICS, Heran HealthTech Fund I, nuclivision, AMARON, icometrix, ONTOFORCE

since 2023

Thibault Jonckheere

Director

since 2023

Clean Vision Invest BV

Director · represented by Bart Swaelens

Also active at: ENPERAS, Pleevi, XBAT.ai

since 2023

Shareholders

Heran HealthTech Fund I

38.4%

Clean Vision Invest

26.2%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Galileilaan 18 box 6

2845 Niel

2.341.387.879

Galileilaan 18

2845 Niel

Active since 27 January 2023

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.

All companies at this address →

NIEUWE MEDIA GROEP

€ 2.2 million revenue · 2025

UNITED CONSULTING

€ 82.2 million revenue · 2025

XPAND

€ 948,746 revenue · 2025

iFLUX

€ 449,843 gross margin · 2025

Vereniging van Mede-eigenaars van het gebouw Residentie Archimedesgebouw Galileilaan 18 te Niel

+6 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0797.707.610
VAT number: BE 0797.707.610
Registered office: Galileilaan 18 bus 6, 2845 Niel
Names & denominations: ImmuneSpec
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 27 January 2023
Peppol: Active · Active since 2 Jul 2025
Activities · NACE: Speur- en ontwikkelingswerk op biotechnologisch gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

ImmuneSpec

Warning lights

Financials

What happened to ImmuneSpec?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions